Edap Tms (NASDAQ:EDAP) Releases Quarterly Earnings Results

Edap Tms (NASDAQ:EDAP) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02), Zacks reports. The business had revenue of $20.48 million during the quarter, compared to analyst estimates of $19.45 million. Edap Tms had a negative return on equity of 116.32% and a negative net margin of 41.47%.

Here are the key takeaways from Edap Tms’ conference call:

• Record Q1 results: The company reported total revenue of $17.8M and record Focal One HIFU revenue of $11.6M (78% YoY HIFU growth), driven by 11 capital sales and a 30% increase in treatment‑driven revenue.
• U.S. procedure volumes rose 53% YoY and EDAP recorded 10 net placements with notable program expansions at UPMC, Moffitt and Mass General Brigham, while international cash sales (France, Hungary, Mexico, U.K.) and multi‑indication demand (prostate cancer and endometriosis) expanded commercial reach.
• HIFI‑2 publication: The largest prospective salvage HIFU study (>500 patients) showed 71% avoided hormone deprivation at 30 months (84% in a selected subgroup), reinforcing clinical value and aligning with NCCN recommendations and current payer reimbursement in the salvage setting.
• Despite improved gross margin (45.7%, +370 bps), operating expenses rose to $15.5M leading to an operating loss of $7.4M and a net loss of $9.1M ($0.24/share); inventory increased and cash fell to $15M at quarter end (partially offset by a ~$14M EIB tranche received post‑quarter).
• Guidance and strategy: Management reiterated 2026 guidance (core HIFU $50–54M; non‑core $22–26M) and emphasized priorities of indication expansion (endometriosis, BPH), technology innovation, and upcoming investor engagement (AUA presence and June 1 investor day).

Edap Tms Stock Down 0.7%

Shares of EDAP stock traded down $0.03 on Friday, reaching $4.13. 65,066 shares of the stock were exchanged, compared to its average volume of 34,415. The company has a current ratio of 1.54, a quick ratio of 1.19 and a debt-to-equity ratio of 0.84. The business’s 50 day moving average price is $3.72 and its 200 day moving average price is $3.37. The company has a market capitalization of $154.79 million, a price-to-earnings ratio of -5.10 and a beta of -0.10. Edap Tms has a twelve month low of $1.21 and a twelve month high of $5.05.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen downgraded shares of Edap Tms from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. HC Wainwright lowered their target price on shares of Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Institutional Investors Weigh In On Edap Tms

A hedge fund recently raised its stake in Edap Tms stock. Rock Springs Capital Management LP boosted its stake in Edap Tms S.A. (NASDAQ:EDAP) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,286,500 shares of the medical equipment provider’s stock after acquiring an additional 16,500 shares during the period. Rock Springs Capital Management LP owned about 3.44% of Edap Tms worth $4,233,000 as of its most recent SEC filing. 62.74% of the stock is owned by hedge funds and other institutional investors.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.